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Abstract  
Abacavir is a nucleoside reverse transcriptase 
inhibitor largely used as part of the antiretroviral 
therapy in Human Immunodeficiency Virus (HIV)-
infected patients. Some individuals (2-9%) who start 
an abacavir treatment show an immunologic 
reaction indicated as hypersensitivity reaction 
syndrome (HSR) that is often responsible for 
therapy discontinuation and could represent a life-
threatening event. Some studies demonstrated a 
correlation between this adverse reaction and the 
class I of the major histocompatibility complex 
(MHC) allele, HLA-B*57.01, in several populations, 
including Caucasians. Nowadays, International HIV 
treatment guidelines recommend the HLA-B*57.01 
genotyping before abacavir administration to reduce 
the incidence of HSR. Both male and female HIV-
infected patients were enrolled at the Infectious 
Diseases Division at the University Hospital of 
Salerno, and admitted to a prospective HLA-
B*57.01 screening. Genetic analysis was carried out 
through two sequential Real-Time PCR reactions in 
which Sybr-Green was used. Out of 248 patients, 
215 were Italians from Southern Italy and 33 were 
coming from several non-EU members countries. 
All were genotyped: 6 Italians (2.8%) and 1 of the 
non-EU group (3%) were identified as HLA-
B*57.01 carriers. In this paper we present our 
experience in the field of abacavir pharmacogenetic 
and confirm the importance of Real Time PCR as a 
valid and cost-effective HLA-B*57.01 typing 
methodology. 
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I. INTRODUCTION 
According to the international HIV treatment 
guidelines, antiretroviral therapy (ART) is 
recommended for Human Immunodeficiency Virus 
(HIV)-infected individuals to reduce the risk of 
disease progression and transmission [1], and 
abacavir (ABC) is currently used as part of the 
combination therapy. Unfortunately, many drugs 
used for the ART are responsible for severe 
hypersensitivity reactions (HSRs) and ABC is not an 
exception [2]. Abacavir is a nucleoside reverse 
transcriptase inhibitor (NRTI) highly active against 
HIV. ABC is generally well tolerated but several 
adverse effects, most of all the HSR, affect its 
clinical use. ABC hypersensitivity reaction (ABC-
HSR) typically involves skin reactions but is also 
characterized by symptoms, such as fever, myalgia 
and gastrointestinal disorders. Moreover, the 
involvement of internal organs with occurrence of 
hepatitis, myocarditis, nephritis etc. has been also 
described. Regardless of the symptoms, ABC-HSR 
affects 2-9% of patients initiating the treatment and 
depends, at least in part, on the genetic background 
of patients [3]. Some studies have described a 
relationship between ABC-HSR and the class I of 
the major histocompatibility complex (MHC) allele, 
HLA-B*57.01 in several populations [4-6] and, 
more recently, a large double blind, prospective 
randomized trial (PREDICT-1 study) has confirmed 
such association [7]. Currently, the Food and Drug 
Administration (FDA), the US Department of Health 
and Human Services and the European Medicines 
Agency (EMA) suggest to adopt an antiretroviral 
agent alternative to ABC for patients bearing the 
HLA-B*57.01 allele (HLA-B*57.01-positive). 
Several molecular methodologies for the screening 
of HLA-B*57.01 have been validated so far. Here 
we show the results from an HLA-B*57.01 
prospective screening, aimed at preventing the 
ABC-HSR, in which Real-Time PCR/melting curve 
with Sybr-Green was used. 
II. METHODOLOGY 
Both female and male HIV-infected patients were 
admitted to a prospective HLA-B*57.01 screening at 
the Laboratory of Molecular Biology of the 
Infectious Diseases Division at the University 
Hospital of Salerno to help reducing the incidence of 
ABC-HSR. None of the patients had previously 
been treated with abacavir.  
Whole blood samples were collected in K2-EDTA-
treated tubes (BD, Milan-Italy) and genomic DNA 
was isolated through MagMax 96 DNA multi 
Sample Kit (Life Tech. Corp.) according to the 
manufacturer’s instructions. DNA concentration was 
measured using the Nano Photometer (IMPLEN, 
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Munich-Germany) and samples were stored at -20°C 
until analysis. 
HLA-B*57.01 genotyping was performed by Real 
Time PCR with Sybr-Green, followed by a melting 
curve determination; the reaction was arranged in 
two sequential steps. First, we detected the presence 
of major histocompatibility class (MHC)-I allotype, 
B*57. The PCR reaction contained 50 ng of total 
DNA, 2x Sybr-Green Master Mix (Life Tech. 
Corp.), 100nM of each primer (1F and 4R) in a 25 
µl final volume. After initial denaturation of 10 min 
at 95°C, a total of 40 PCR cycles were performed 
using the following conditions (95°C for 15 s and 
annealing/extension at 60°C for 1 min). The second 
PCR reaction was carried out to identify B*57.01 
carriers in B*57 positive samples previously 
validated by melting curve analysis (~Tm 87.1 °C). 
In this case, the PCR reaction contained 25ngof total 
DNA, 2x Sybr-Green Master Mix (Life Tech. 
Corp.), 200nM of each primer (indicated as 1F, 2R 
and 3R) in a 25 µl final reaction volume; the 
conditions used were the same as described for the 
first PCR. Data from the second PCR reaction were 
verified by melting curve analysis (~Tm 85.1°C). 
PCR reactions were performed using an Applied 
Biosystems (ABI) 7500 Real-time PCR System 
(Life Tech. Corp.). Sequence-specific primers were 
synthesized according to the sequence reported by 






A total of 248 HIV-infected patients (66 women and 
182 men) were enrolled and admitted to this 
prospective HLA-B*57.01 screening for the 
prevention of ABC-correlated HSR. 215 individuals 
were Italians from Southern Italy, 33 were non-EU. 
None of the patients had previously received a 
treatment with abacavir. HLA-B*57.01 frequency 
values were similar in both Italians (2.8%) and non-
EU (3.0%). In Figure 1 amplification plots (panels A 
and C) and the corresponding melting curve (panels B 
and D) were showed. 
 
IV. DISCUSSION 
Since 1998 abacavir has been used by almost 1 
million HIV-infected patients [9]. This antiretroviral 
agent is generally well tolerated, but some patients 
develop an immunologic reaction, indicated as 
ABC-HSR, usually within the first 6 weeks of 
treatment. ABC-HSR is a relatively dose-
independent adverse reaction generally 
characterized by fever, rash, gastrointestinal and/or 
respiratory symptoms [10]. It may be threatening 
and in some cases can cause death, especially in the 
case of re-challenge reaction due to ABC 
reintroduction. Moreover, the ABC-HSR diagnosis 
is complicated by the fact that there is a lack of 
specific signs and symptoms and, notably, the 
concomitant use of other antiretroviral drugs can be 
responsible for overlapping adverse events [11,12]. 
Because only a minority (2-9%) of patients develops 
this immunologic reaction, it was hypothesized that 
individual characteristics could also play an 
important role. In addition, some epidemiologic 
studies identified racial differences responsible for 
the different risk to develop ABC-HSR. From 2002, 
worldwide studies have reliably showed that HLA-
B*57.01 is important to predict the hypersensivity 
reactions to abacavir [4,5,7,13].  
Interestingly, while a high frequency of HLA-
B*57.01 allele was found in white people, the same 
was not observed in black ones [14]. On the other 
hand, an almost 100% sensitivity of HLA-B*57.01 
as a marker to predict the individual patient’s risk 
for ABC-HSR was confirmed in both US white and 
black people, suggesting the existence of a real 
clinical utility of this genetic screening in both races 
[15]. 
The prevalence of HLA-B*57.01 carriers greatly 
varies (from 2 to 9%) in different ethnic/geographic 
groups [16]. We found an HLA-B*57.01 frequency 
of 2.8% in patients coming from Southern Italy. 
For what concerning HLA-B*57.01 carriers in the 
group of non-EU patients, we found an allelic 
frequency of ~3%, a value that is quite similar to 
that obtained for the Italian group. However, it is 
worth to note that this value is referred to a mixed 
group that includes individuals coming from several 
non-EU member countries. 
It has been estimated that in the absence of a genetic 
prospective screening, ABC-HSR might affect ca. 
6% of patients. As a consequence, the 
pharmacogenetic screening for HLA-B*57.01 is 
now recommended before starting ABC therapy in 
both adult and adolescent HIV-infected patients 
[17]. 
Regrettably, in spite of the fact that HLA-B*57.01 
genotyping is a cost effective analysis that is useful 
in preventing ABC-HSR [18,19], it is still an 
underused clinical practice.
 
Since the HLA locus is extremely polymorphic, it is 
difficult to discriminate HLA-B*57.01 from related 
alleles. In recent years several molecular genetic 
methodologies, such as sequence specific 
amplification [20], allele-specific polymerase chain 
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reaction (AS-PCR)/melting curve [21] and many 
others, have been proposed. In our laboratory we 
have successfully used, and continue to utilize, a 
Real-Time PCR technique with Sybr-Green for the 
identification of HLA-B*57.01 carriers. 
The Real-Time PCR was recognized as a very fast 
(the reaction is complete in 2-3h) and cost-effective 
screening technique with an average reagent cost of 
about 16 Euros [22]. Our experience confirm that it 
is a quick and reliable technique to screen  HLA-




Abacavir is one of the brightest examples of 
“translation” of basic research studies into clinical 
practice. 
HLA-B*57.01 screening before abacavir 
administration has been shown to be of great clinical 
utility, and it is now officially recommended in 
clinical guidelines and routinely performed in most 
Western countries. 
Although genotyping should not substitute the 
clinical vigilance, it greatly reduces the incidence of 
ABC-HSR by identifying, before starting the 
therapy, patients at high risk of developing such 
adverse reaction. We hope that our laboratory 
experience, here reported, may positively contribute 
to the clinical use of this specific genotyping in the 
more general framework of pharmacogenetic 
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Figure 1 amplification plots (panels A and C) and the corresponding melting curve (panels B and D)
 
 
